Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. - Wikidata - awgldk - TriplyDB

Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.

Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.

http://www.wikidata.org/entity/Q33728782

about

A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.

P2860

Q45796639-12563BAE-08ED-4616-AFAF-899ED6EACC48

P2860

Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.

http://www.wikidata.org/entity/Q33728782

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@ast

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@en

type

label

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@ast

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@en

prefLabel

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@ast

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@en

P1433

Q33728782-1C5875BD-7D2F-4D02-BAC0-88278035819A

P1476

Q33728782-9F1E4627-F97B-4836-9722-691FD765A324

P2093

Q33728782-06544DA9-5DAF-49DF-BBB7-11BFB44FA9FB

Q33728782-101B03E6-F52D-4499-8494-F752754706D6

Q33728782-1E53B472-F9A4-4548-8FCD-8FD864F8792C

Q33728782-1FFB381D-9878-46F1-9AFE-8CF17D389FE7

Q33728782-5CC500F2-F160-429F-B5EE-565C87ACB472

Q33728782-7EB747EF-FB95-43A3-9D77-EBF353CEB483

Q33728782-94DD3098-82B9-46C1-8B92-F7BFF8069138

Q33728782-D08658DF-4E56-4FA1-9F5C-D43F64915876

Q33728782-F8D979A9-E46E-40AB-817A-C95612812CB0

P2860

Q33728782-011CC50B-8D43-4BDF-A04C-D19CE255D0E1

Q33728782-1400B46C-2CBC-4072-BAA6-3194EE0BD558

Q33728782-27C21801-950E-4A2B-A50E-FC06BE9DE2E6

Q33728782-53E43A27-B8A6-440F-852D-1DE41F3EA388

Q33728782-7C9C8E0F-2284-4852-86B2-B7F6F62BBCE7

Q33728782-7F38B159-9A22-489F-A540-BE20F5E25D76

Q33728782-841728E0-766A-409D-A943-B9772B05CF9B

Q33728782-91FD3BCE-6C76-41E7-A1ED-6AE495829C9D

Q33728782-947FB925-C993-47BE-9347-BEDF9162A3BF

Q33728782-994C1C3A-31D5-4BC5-B8B3-A6D06C535391

P2888

Q33728782-D04EF315-6F93-4BAE-8499-40A6AE9E54EF

P304

Q33728782-C1458EFC-77D2-48B6-B5AB-52221BAD40EA

P31

Q33728782-5DFD33A6-B20A-4ED8-9EE6-102B48BCDEC0

P356

Q33728782-33E994FD-E365-423B-B49C-4DCC3C99C8C7

P478

Q33728782-82751914-3E60-4304-9D92-81EB2EFBC0C0

P577

Q33728782-9495BC89-DB87-4AD8-BFFF-BF0DC0C4A411

P5875

Q33728782-6ADF2434-2BB1-4A40-B6EA-39D165C8C00A

P6179

Q33728782-98AC6634-DE59-438A-8A74-5AF70F573F28

P698

Q33728782-6CB49697-0A5C-4BC6-B7D3-35E7083709D9

P932

Q33728782-DC864004-D7DC-403B-9E32-574899FF0C8A

P356

1756-9966-29-15

P1433

Journal of Experimental & Clinical Cancer Research

P1476

Plasma pharmacokinetics after ...... nresectable pancreatic cancer.

@en

P2093

Bunzo Nakata

http://www.w3.org/2001/XMLSchema#string

Kosei Hirakawa

http://www.w3.org/2001/XMLSchema#string

Nobuya Yamada

http://www.w3.org/2001/XMLSchema#string

Osamu Shinto

http://www.w3.org/2001/XMLSchema#string

Ryosuke Amano

http://www.w3.org/2001/XMLSchema#string

Shigetomi Nakao

http://www.w3.org/2001/XMLSchema#string

Tatsuro Tamura

http://www.w3.org/2001/XMLSchema#string

Toshiki Hirakawa

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Okita

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.

Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.

Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.

Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.

Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.

P2888

1756-9966-29-15

P304

15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-29-15

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41561537

http://www.w3.org/2001/XMLSchema#string

P6179

1012931039

http://www.w3.org/2001/XMLSchema#string

P698

20181235

http://www.w3.org/2001/XMLSchema#string

P932

2838818

http://www.w3.org/2001/XMLSchema#string